Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Clinical trial NCT03833154 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03833154
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2019-03-06
Primary completion: 2028-10-31
Enrollment: 724

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.